Overview
Asiri Surgical Hospital operates a specialist private hospital serving surgical, diagnostic and post-operative care needs. The latest filed quarter showed a marked strengthening in profitability, led by higher revenue and record gross and net margins against its own comparable September history.
The market-wide valuation starting point is Fairly valued, scoring 55 out of 100 across book value, earnings and dividends. The evidence moves the assessment to bullish because operating performance and balance-sheet repair are stronger than that middle-of-market starting point suggests.
Price performance
At LKR 13.40 on 10 November 2026, AMSL was down 43.7% over six months, compared with a 6.7% fall in the ASPI. It has nevertheless risen 32.7% over one month against a 6.0% ASPI gain, showing that the recent rebound follows a much larger earlier retreat rather than a consistently stronger record.
The price sits 22.0% up its 52-week range from the low, leaving it near the lower end of that range. The three-year record contains four falls of 15% or more, with the deepest decline 64.1% and not yet recovered; these are records of past volatility, not price levels.
Median daily turnover was LKR 1.7 million over 60 sessions. A LKR 1 million order is about 59% of what trades on a typical day, a large part of a day's trading.
Valuation
At 8.7 times P/E, AMSL asks for LKR 8.70 for every LKR 1 of trailing profit, below the healthcare peer median of 13.9 times. Its P/B of 0.87 means the market value is 87 cents for each rupee of net assets, against a sector median of 2.01, while audited FY2026 return on equity was 10.7%; the lower P/B is therefore not simply explained by an unusually weak return on equity.
The company’s own P/E record says it is cheaper than 68% of days since February 2012. A buyer at the present multiple is relying on a September quarter that provided 33.6% of trailing EPS; if that quarter had earned its year-ago net margin, P/E would be 9.4 times instead.
There is no current dividend yield and no dividend is on record in the last two years. That removes income from the valuation case despite the share's lower earnings and book multiples.
News and sentiment
Direct coverage is thin: the 90-day news set contains three material articles, one positive and two negative. The most material item, reported on 17 August 2026, concerned Softlogic Holdings and noted that a tax dispute involving Asiri Surgical Hospital remains under appeal.
There are no confirmed or undated corporate actions in the supplied record, and no dividend is currently on record.
Financials
September-quarter revenue rose 17.6% year-on-year to LKR 2.3 billion, while net profit increased 50.2% to LKR 360 million. Gross margin improved from 43.8% to 45.5%, operating margin was 18.1% with no comparable prior-year operating margin available in the filed series, and net margin improved from 12.1% to 15.4%. Gross margin was the best of seven comparable September quarters and net margin among the best two of seven, so this was not merely a nominal revenue increase.
The LKR 64 million gap between operating and net profit shows finance costs, tax and other below-operating items still reduced earnings, but the latest quarter retained most of its operating profit. LKR 37 million of group profit belonged to minority shareholders, so group profit is not wholly attributable to the ordinary shares being valued.
At the latest audited year-end, revenue was LKR 7.7 billion and net profit LKR 940 million, up 151.6% year-on-year. Equity attributable to owners was LKR 7.6 billion, and the share count was unchanged at 528.5 million between the latest balance sheet and today, so the reported per-share figures are not being mechanically reshaped by a recent rights issue or subdivision.
Risks
The main financial risk is cash conversion. In FY2026, operating cash flow was only 0.33 times operating profit and free cash flow was negative LKR 95 million, meaning accounting profit did not largely arrive as cash after capital spending. For a hospital that invests in clinical facilities, that leaves future cash generation important even though reported earnings improved.
Debt is less burdensome than a year earlier: net debt was LKR 1.2 billion and gearing was 24.2% of owners' equity. Interest cover was 4.78 times, meaning operating profit covered the finance bill fewer than five times, while the 1.09 current ratio left only a modest excess of short-term assets over bills due within a year.
The wider market backdrop adds a cost risk. As at 10 November 2026, inflation was 8.3% after a 100 basis-point policy-rate increase; this is market context rather than company-specific news, but higher borrowing and operating costs would matter to a capital-intensive hospital.
Outlook
As at 10 November 2026, the next documented catalyst is the interim quarter ending 31 December 2026, expected to be filed between 3 and 14 February 2027. It will show whether the stronger September revenue and profitability were sustained and whether operating cash generation improved; the supplied data cannot establish either outcome in advance.
The unresolved tax dispute cited in the 17 August report remains a separate uncertainty because its potential financial terms are not supplied. Healthcare-sector news was otherwise quiet, providing no company-specific evidence on demand, pricing or expansion beyond the filed results.